Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

523
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
523
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

860
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of vacuum OLTC faults using improved multimodal PKO-SVM.

Scientific reports·2026
Same author

An <i>n</i>-Type Ionic Thermoelectric Device Enabled by Synergistic Interactions Between Electrodes and PVA Hydrogel.

Materials (Basel, Switzerland)·2026
Same author

Myocardial injury predicts mortality in elderly carbon monoxide poisoning: development and internal validation of a simple prognostic model.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2026
Same author

Picosecond all-electrical perpendicular magnetization switching.

Nature communications·2026
Same author

Arabidopsis DXO1- and RNMT1-Mediated m<sup>7</sup>G Capping of mRNA Modulates ABA Response.

Plant, cell & environment·2026
Same author

Risk stratification for myocardial injury and mortality in acute carbon monoxide poisoning: a multivariable predictive model.

Inhalation toxicology·2026

Related Experiment Video

Updated: Nov 17, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K

A Novel Framework to Predict Breast Cancer Prognosis Using Immune-Associated LncRNAs.

Zhijian Huang1,2, Chen Xiao3, Fushou Zhang4

  • 1Department of Breast Surgical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.

Frontiers in Genetics
|February 15, 2021
PubMed
Summary

This study identifies a novel immune-associated long non-coding RNA (lncRNA) signature for predicting breast cancer (BC) patient survival. This signature accurately forecasts prognosis and correlates with immune cell infiltration in breast cancer.

Keywords:
GEOTCGAbreast cancerframeworkimmuneprognosisrisk score

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

342
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Related Experiment Videos

Last Updated: Nov 17, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

342
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Area of Science:

  • Oncology
  • Genomics
  • Immunology

Background:

  • Breast cancer (BC) is a heterogeneous malignancy requiring reliable molecular biomarkers for patient stratification.
  • Identifying immune-associated long non-coding RNAs (lncRNAs) offers potential therapeutic targets for BC.

Purpose of the Study:

  • To develop and validate an immune-associated lncRNA signature for predicting breast cancer prognosis.
  • To assess the signature's correlation with immune cell infiltration and its independence from clinicopathological factors.

Main Methods:

  • Utilized TCGA database for lncRNA expression and clinical data from BC patients.
  • Developed a prognostic model using univariate and Lasso Cox regression analyses.
  • Validated the model in independent cohorts and constructed a nomogram integrating clinical factors.

Main Results:

  • The developed immune-associated lncRNA signature significantly predicted overall survival (OS) in BC patients.
  • The signature's predictive performance was independent of clinicopathological factors.
  • The signature demonstrated a significant correlation with immune cell infiltration in the tumor microenvironment.

Conclusions:

  • An immune-associated lncRNA signature was successfully constructed for accurate breast cancer prognosis prediction.
  • This signature serves as an independent prognostic marker and is linked to immune cell infiltration patterns.